Physician profile
Charles Brooks Smith
NPI 1790780930
$9,099.42
in general payments reported to CMS, 2019-2025
62 companies · $1,208 in 2025
The $1,208 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $562 · 2021: $1,472 · 2022: $1,630 · 2023: $1,488 · 2024: $1,711 · 2025: $1,208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,389 · Entertainment: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,389.49 |
| Entertainment | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,338.03 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $903.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $748.32 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $595.66 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $491.60 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $420.64 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $371.91 | 2019-2025 | Rexulti, Abilify Maintena |
| Amarin Pharma, INC. | $352.44 | 2019-2022 | |
| Amgen INC. | $344.27 | 2019-2025 | Otezla, Repatha, Otezla |
| Exact Sciences Corporation | $320.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $306.16 | 2022-2025 | Freestyle Libre, Proclaim |
| Astellas Pharma US INC | $241.53 | 2019-2022 | |
| Pfizer INC. | $239.41 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $161.23 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $153.71 | 2021-2024 | Livalo, Seglentis |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.